Navigation Links
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
Date:7/31/2008

e year to December 31, 2007.

VYVANSE - ADHD

VYVANSE was launched in the US market in July 2007. Product sales for the three months to June 30, 2008 were $65.2 million (2007: $nil) representing a 20% increase compared to sales of $54.4 million in Q1 2008.

Product sales growth was driven by a 15% increase in prescription demand compared to Q1 2008 together with a price increase in May 2008. For the three months to June 30, 2008 VYVANSE's average quarterly market share was 7.4% (Q1 08: 6.1%) of the US ADHD market.

By July 18, 2008 VYVANSE had achieved a US ADHD average weekly market share of 8.2% based on weekly prescription volumes.

DAYTRANA - ADHD

Product sales for the three months to June 30, 2008 were $22.6 million (2007: $19.9 million). Prescriptions declined by 11% from the same period last year due to a reduction in DAYTRANA's average quarterly market share of the US ADHD market to 1.8% (2007: 2.2%).

Despite the decrease in prescriptions compared to 2007, sales of DAYTRANA grew 14% due to higher market growth, lower sales deductions and a price increase in January 2008.

On June 9, 2008 Shire announced a voluntary recall of a limited portion of DAYTRANA patches because certain patches did not meet their release liner removal specifications which may have resulted in some patients and caregivers having difficulties removing the liners. The voluntary recall was not due to safety issues. Shire and Noven Pharmaceuticals Inc. (the manufacturer of DAYTRANA) continue to pursue enhancements to the product and to work closely with the FDA to implement changes that may improve the usability of DAYTRANA. No interruption in the production of DAYTRANA is anticipated.

US oral mesalamine market share

Shire's average quarterly market share of the US oral mesalamine market rose to 27.6% in the three months to June 30, 2008 (2007: 19.9%), driven by the introduction of LIALDA in March 2007. The overall US oral me
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009).... 6 Intarcia Therapeutics, Inc. de...UROS® continuous delivery of exenatide) progr...th Annual Diabetes Technology Meeting in San Franc...-bin/prnh/20050301/SFTU126LOGO ) ,, Continuou...Lowers Plasma Glucose, HbA1c and Reduces Weight in...
(Date:11/5/2009)...ov. 5 GenVec, Inc. (Nasd...for the third quarter ended September 30, 2009. Ge...r share) for the three months ended September 30, ... per share) in the comparable quarter of 2008. For...s net loss was $14.1 million ($0.15 per share), co...
(Date:11/5/2009)...RNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bull...encer, President and CEO of Imagenetix, will be pr...MICRO Conference on Thursday, December 3rd, at 10:... About LD MICRO ,, LD MICRO is a by-invitation ...valued companies in the micro-cap space. Since 200...
(Date:11/5/2009)... Transgenomic, Inc. (OTC ...sults for the quarter ended September 30, 2009. Th... tables that follow. ,, Third Quarter 2009 ,... $0.01 per share for the third quarter of 2009 as ...are for the third quarter of 2008. ,, Net sale...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...ied for A1c testing using dried blood spot,specime...nternational LLC, a division of Hooper Holmes (Ame...emoglobin A1c testing methods by the National,Glyc...tage Labs uses two blood testing methods for hemog...nd the other for testing dried blood,spots (DBS), ...
...Nov. 11 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIG...esident and chief executive officer, will present ...hcare Conference on Thursday,November 13 at 4:30 p...a,Biltmore Resort in Phoenix, Arizona., To access... recording,log on to http://www.rigel.com . Pleas...
...hera Pharmaceuticals, Inc.,a privately held biopha...rugs, today announced new data on its lead product...ation (AHA) Annual Conference in New Orleans,Louis... varespladib for the,treatment of coronary heart d...laborators released new data from the Phase II PLA...
Other Biology Technology:Heritage Labs Announces A1c Test Certification Milestone 2Heritage Labs Announces A1c Test Certification Milestone 3Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease 2
(Date:11/4/2009)...n has received more than $10 million in research g...deral stimulus program, bringing thetotal amount o...23 million. Thirty-three projects achieved stimul... weather. , "The university has thoughtfully und...scholarly excellence to federal agency priorities....
(Date:11/4/2009)...e/ -- What,s the cost of saving a teenage life? Wh...ng from prescription medication abuse, there,s no ...may be unaware that the lock-boxes they,ve install... timebomb of prescription drugs. That,s why MEDNET... supplies, has formed an exclusive partnership wit...
(Date:11/4/2009)...swire/ -- GenVault Corporation (Carlsbad, CA) toda...oined its Board of Directors. Dr. Brody, the Irwi... is an acclaimed physician-scientist and universit.... Brody served as president of The Johns Hopkins U... of Engineering and the Institute of Medicine, and...
Breaking Biology News(10 mins):OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Sinovac Adjourns 2008 Annual General Meeting 13056 1Sinovac Adjourns 2008 Annual General Meeting 13056 2AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimers Disease 51870 1AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimers Disease 51870 2AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimers Disease 51870 3Tennis Elbow Shin Splints and Carpal Tunnel Syndrome Could Be a Thing of the Past Due to New Efforts with Sports Musculoskeletal Ultrasound 51869 1Tennis Elbow Shin Splints and Carpal Tunnel Syndrome Could Be a Thing of the Past Due to New Efforts with Sports Musculoskeletal Ultrasound 51869 2Tennis Elbow Shin Splints and Carpal Tunnel Syndrome Could Be a Thing of the Past Due to New Efforts with Sports Musculoskeletal Ultrasound 51869 3Tennis Elbow Shin Splints and Carpal Tunnel Syndrome Could Be a Thing of the Past Due to New Efforts with Sports Musculoskeletal Ultrasound 51869 4
...rking lots may look better with a layer of sealcoa...ff the surface into nearby streams will be carryin...w research conducted at the University of New Hamp...lcoat may contribute to increasingly significant a...ways from stormwater runoff. , Polyaromatic hydro...
...gene that controls the rapid production and differ... cell types -- a discovery that could eventually o...ukemia and other blood cancers, in which blood cel...n investigating the mechanisms of this gene, the s...protocol for bone marrow transplants that could bo...
...es for capitalizing on environmentally friendly fa...l waste to produce jobs, economic growth, commerci...cording to a perspective article published in the ...vate Law . , Ronald Griffin, Professor of Law at ... leaders do for a desperate and aging population i...
Other Biology News:UNH: Pavement sealcoat a source of toxins in stormwater runoff 2Scientists identify key gene that protects against leukemia 2Scientists identify key gene that protects against leukemia 3Ma and Pa solutions to global warming 2
...aging and analysis system is an integrated hardwar...pid acquisition and analysis of fluorescence image...Xpress is fast. Scanning an entire 384-well plate ...fluorescence images per well, takes less than 13 m...
Earle's Balanced Salt Solution, 10x (EBSS) from Sigma-Aldrich
...lined immunospot) Kit analyzes interferon gamma (I...spot forms at the site where secreted cytokine is ...scope or automated ELISPOT reader) and then compar... This allows the frequency of cells secreting the ...
Corning Roller Bottle Easy Grip Caps, Sterile from Sigma-Aldrich
Biology Products: